论文部分内容阅读
目的探讨乙型肝炎(乙肝)标志物定量检测指标与乙肝病毒脱氧核糖核酸(HBV-DNA)定量、丙氨酸氨基转移酶(ALT)的关系,为临床治疗乙肝提供参考。方法 185例门诊、住院及体检者,抽取静脉血,血液标本采用PCR-荧光探针法进行HBV-DNA含量测定,同时采用时间分辨荧光免疫测定法(TRFIA)及酶法进行两对半指标及ALT检测,对比分析检测结果。结果 185例乙肝患者的血液标本中,大三阳45例;小三阳111例;1,5阳性模式22例;1,2,3,5阳性模式2例;1,2,4,5模式5例;HBV-DNA检测阳性率为73.5%(136/185)。结论在乙型肝炎表面抗原(HBs Ag)均为阳性的情况下,乙型肝炎e抗原(HBe Ag)阳性率与HBV-DNA定量及ALT有关,为临床制定合理的乙肝治疗方素提供了依据,有利于抑制乙肝病毒的传染。
Objective To explore the relationship between quantitative detection of hepatitis B (HBV) markers and HBV-DNA quantitative and alanine aminotransferase (ALT), and to provide a reference for clinical treatment of hepatitis B. Methods 185 cases of outpatients, inpatients and physical examination were drawn venous blood and blood samples by PCR-fluorescence probe for determination of HBV-DNA content, time-resolved fluorescence immunoassay (TRFIA) and enzymatic method for two pairs of semi-targets and ALT test, comparative analysis of test results. Results Among the 185 cases of hepatitis B patients, 45 cases were positive in Big Sanyang, 111 cases in Xiaosanyang, 22 cases in 1, 5 positive mode, 2 cases in 1, 2, 3 and 5 cases, 2 cases in 1, 2, 4 and 5 cases Cases; HBV-DNA test positive rate was 73.5% (136/185). Conclusion The positive rate of hepatitis B e antigen (HBeAg) is related to the quantification of HBV DNA and ALT in the case of HBsAg positive, which provides a basis for the development of a reasonable hepatitis B therapeutic hormone , Is conducive to the suppression of hepatitis B virus infection.